Risk of invasive Haemophilus influenzae type b (Hib) disease in adults with secondary immunodeficiency in the post-Hib vaccine era

Clinical and Vaccine Immunology

Volumn 19, Issue 5, 2012, Pages 766-771

  Nix, Eli B ^a   Hawdon, Nicole ^a   Gravelle, Sean ^a   Biman, Birubi ^a   Brigden, Malcolm ^a   Malik, Saleem ^a   McCready, William ^a   Ferroni, Garry ^a   Ulanova, Marina ^a  

^a LAKEHEAD UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOGLOBULIN G;

ADULT; AGED; ANTIBACTERIAL ACTIVITY; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BACTERIAL TRANSMISSION; CHRONIC KIDNEY FAILURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE TYPE B; HIGH RISK PATIENT; HUMAN; IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION PREVENTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

ADULT; AGED; ANTIBODIES, BACTERIAL; BACTERIAL CAPSULES; BLOOD BACTERICIDAL ACTIVITY; DIABETES MELLITUS, TYPE 2; FEMALE; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RENAL INSUFFICIENCY; RISK ASSESSMENT;

EID: 84860319956     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05675-11     Document Type: Article

References (50)

1. Adam HJ, et al. 2010. Changing epidemiology of invasive Haemophilus influenzae in Ontario, Canada: Evidence for herd effects and strain replacement due to Hib vaccination. Vaccine 28:4073-4078.
2. Amir J, Liang X, Granoff DM. 1990. Variability in the functional activity of vaccine-induced antibody to Haemophilus influenzae type b. Pediatr. Res. 27:358-364. (Pubitemid 20114010)
3. Anderson P. 1984. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J. Infect. Dis. 149: 1034-1035.
4. Bender JM, et al. 2010. Invasive Haemophilus influenzae disease in Utah children: An 11-year population-based study in the era of conjugate vaccine. Clin. Infect. Dis. 50:e41-e46.
5. Castle SC. 2000. Clinical relevance of age-related immune dysfunction. Clin. Infect. Dis. 31:578-585. (Pubitemid 32289594)
6. Chalmers C. 2010. Necrotising fasciitis complicating Haemophilus influenzae type b epiglottitis in an adult. J. Laryngol Otol. 124:807-809.
7. Chew CG, Clarkson AR, Faull RJ. 1997. Relapsing CAPD peritonitis with rapid peritoneal sclerosis due to Haemophilus influenzae. Nephrol. Dial. Transplant. 12:821-822. (Pubitemid 27170450)
8. Cutolo M, et al. 2008. Use of glucocorticoids and risk of infections. Autoimmun. Rev. 8:153-155.
9. Dalrymple LS, Go AS. 2008. Epidemiology of acute infections among patients with chronic kidney disease. Clin. J. Am. Soc. Nephrol. 3:1487-1493.
10. Denoel PA, et al. 2007. Quality of the Haemophilus influenzae type b (Hib) antibody response induced by diphtheria-tetanus-acellular pertussis/ Hib combination vaccines. Clin. Vaccine Immunol. 14:1362-1369. (Pubitemid 350012980)
11. Dentinger CM, et al. 2006. Immunogenicity and reactogenicity to Haemophilus influenzae type B (Hib) conjugate vaccine among rural Alaska adults. Hum. Vaccin. 2:24-28. (Pubitemid 43667662)
12. Dworkin MS, Park L, Borchardt SM. 2007. The changing epidemiology of invasive Haemophilus influenzae disease, especially in persons > or = 65 years old. Clin. Infect. Dis. 44:810-816. (Pubitemid 46365305)
13. Frasca D, Riley RL, Blomberg BB. 2005. Humoral immune response and B-cell functions including immunoglobulin class switch are downregulated in aged mice and humans. Semin. Immunol. 17:378-384. (Pubitemid 41058769)
14. Hallander HO, Lepp T, Ljungman M, Netterlid E, Andersson M. 2010. Do we need a booster of Hib vaccine after primary vaccination? A study on anti-Hib seroprevalence in Sweden 5 and 15 years after the introduction of universal Hib vaccination related to notifications of invasive disease. APMIS 118:878-887.
15. Insel RA, and Anderson PW, Jr. 1982. Cross-reactivity with Escherichia coli K100 in the human serum anticapsular antibody response to Haemophilus influenzae type B. J. Immunol. 128:1267-1270. (Pubitemid 12188449)
16. Joshi N, Caputo GM, Weitekamp MR, Karchmer AW. 1999. Infections in patients with diabetes mellitus. N. Engl. J. Med. 341:1906-1912.
17. Karlsson J, et al. 2011. Comparative study of immune status to infectious agents in elderly patients with multiple myeloma, Waldenstrom's macroglobulinemia, and monoclonal gammopathy of undetermined significance. Clin. Vaccine Immunol. 18:969-977.
18. Kato S, et al. 2008. Aspects of immune dysfunction in end-stage renal disease. Clin. J. Am. Soc. Nephrol. 3:1526-1533.
19. Kayhty H, Peltola H, Karanko V, Makela PH. 1983. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J. Infect. Dis. 147:1100. (Pubitemid 13068358)
20. Leino T, Auranen K, Makela PH, Kayhty H, Takala AK. 2000. Dynamics of natural immunity caused by subclinical infections, case study on Haemophilus influenzae type b (Hib). Epidemiol. Infect. 125:583-591. (Pubitemid 32156848)
21. Lottenbach KR, et al. 2004. Safety and immunogenicity of Haemophilus influenzae type B polysaccharide or conjugate vaccines in an elderly adult population. J. Am. Geriatr. Soc. 52:1883-1887. (Pubitemid 41710273)
22. Lucas AH, et al. 1991. An idiotypic marker associated with a germ-line encoded kappa light chain variable region that predominates the vaccineinduced human antibody response to the Haemophilus influenzae b polysaccharide. J. Clin. Invest. 88:1811-1818.
23. MacNeil JR, et al. 2011. Current epidemiology and trends in invasive Haemophilus influenzae disease-United States, 1989-2008. Clin. Infect. Dis. 53:1230-1236.
24. Maslanka SE, et al. 1998. Age-dependent Neisseria meningitidis serogroup C class-specific antibody concentrations and bactericidal titers in sera from young children from Montana immunized with a licensed polysaccharide vaccine. Infect. Immun. 66:2453-2459. (Pubitemid 28261738)
25. Meerveld-Eggink A, de Weerdt O, van Velzen-Blad H, Biesma DH, Rijkers GT. 2011. Response to conjugate pneumococcal and Haemophilus influenzae type b vaccines in asplenic patients. Vaccine 29:675-680.
26. Meerveld-Eggink A, et al. 2009. Antibody response to polysaccharide conjugate vaccines after nonmyeloablative allogeneic stem cell transplantation. Biol. Blood Marrow Transplant. 15:1523-1530.
27. Moxon ER. 1986. The carrier state: Haemophilus influenzae. J. Antimicrob. Chemother. 18(Suppl. A):17-24. (Pubitemid 16038219)
28. Murphy TF. 2005. Haemophilus infections, p 2661-2669. In Mandell GL, Douglas RG, Bennett JE, Dolin R (ed), Mandell, Douglas, and Bennett's principles and practice of infectious diseases, 6th ed, vol 2. Elsevier, New York, NY.
29. Neuhaus TJ, Iselin H, Nadal D. 1996. Haemophilus influenzae: A cause of peritonitis in peritoneal dialysis. Nephrol. Dial. Transplant. 11:199-200. (Pubitemid 26038491)
30. Nucci M, Anaissie E. 2009. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin. Infect. Dis. 49: 1211-1225.
31. Oh SY, et al. 2008. School-aged children: A reservoir for continued circulation of Haemophilus influenzae type b in the United Kingdom. J. Infect. Dis. 197:1275-1281. (Pubitemid 351632758)
32. Park S, Nahm MH. 2011. Older adults have a low capacity to opsonize pneumococci due to low IgM antibody response to pneumococcal vaccinations. Infect. Immun. 79:314-320.
33. Peltola H, Kayhty H, Virtanen M, Makela PH. 1984. Prevention of Hemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine. N. Engl. J. Med. 310:1561-1566. (Pubitemid 14117336)
34. Public Health Agency of Canada. 2006. Canadian Immunization Guide, 7th ed. Public Health Agency of Canada, Ottawa, Canada.
35. Resman F, et al. 2011. Invasive disease caused by Haemophilus influenzae in Sweden 1997-2009; evidence of increasing incidence and clinical burden of non-type b strains. Clin. Microbiol. Infect. 17:1638-1645.
36. Robertson JD, et al. 2000. Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. Br. J. Cancer 82:1261-1265. (Pubitemid 30145342)
37. Romero-Steiner S, et al. 2001. Functional antibody activity elicited by fractional doses of Haemophilus influenzae type b conjugate vaccine (polyribosylribitol phosphate-tetanus toxoid conjugate). Clin. Diagn. Lab. Immunol. 8:1115-1119. (Pubitemid 33035741)
38. Romero-Steiner S, et al. 2004. Measurement of serum bactericidal activity specific for Haemophilus influenzae type b by using a chromogenic and fluorescent metabolic indicator. Clin. Diagn. Lab. Immunol. 11:89-93. (Pubitemid 38090657)
39. Rubach MP, et al. 2011. Increasing incidence of invasive Haemophilus influenzae disease in adults, Utah, U. S. A. Emerg. Infect. Dis. 17:1645-1650.
40. Saito T, et al. 2009. Necrotizing fasciitis caused by Haemophilus influenzae type b in an elderly patient. J. Clin. Microbiol. 47:852-854.
41. Schreiber JR, Barrus V, Cates KL, Siber GR. 1986. Functional characterization of human IgG, IgM, and IgA antibody directed to the capsule of Haemophilus influenzae type b. J. Infect. Dis. 153:8-16. (Pubitemid 16212447)
42. Sethi S. 2010. Infection as a comorbidity of COPD. Eur. Respir. J. 35: 1209-1215.
43. Shapiro ED, Ward JI. 1991. The epidemiology and prevention of disease caused by Haemophilus influenzae type b. Epidemiol. Rev. 13:113-142.
44. Shuel M, Hoang L, Law DK, Tsang R. 2011. Invasive Haemophilus influenzae in British Columbia: Non-Hib and non-typeable strains causing disease in children and adults. Int. J. Infect. Dis. 15:e167-e173.
45. Shuel M, et al. 2010. Characterization of nontypeable Haemophilus influenzae collected from respiratory infections and invasive disease cases in Manitoba, Canada. FEMS Immunol. Med. Microbiol. 58:277-284.
46. Takala AK, Eskola J, van Alphen L. 1990. Spectrum of invasive Haemophilus influenzae type b disease in adults. Arch. Intern. Med. 150:2573-2576.
47. Ulanova M, Hahn-Zoric M, Lau YL, Lucas A, Hanson LA. 1996. Expression of Haemophilus influenzae type b idiotype 1 on naturally acquired antibodies. Clin. Exp. Immunol. 105:422-428. (Pubitemid 26297885)
48. Ulanova M, Tsang RS. 2009. Invasive Haemophilus influenzae disease: Changing epidemiology and host-parasite interactions in the 21st century. Infect. Genet. Evol. 9:594-605.
49. van Belle G. 2008. Statistical rules of thumb, 2nd ed. John Wiley & Sons Inc, Hoboken, NJ.
50. Weinberger B, Herndler-Brandstetter D, Schwanninger A, Weiskopf D, Grubeck-Loebenstein B. 2008. Biology of immune responses to vaccines in elderly persons. Clin. Infect. Dis. 46:1078-1084. (Pubitemid 351589876)